AU2003221684A1 - Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor - Google Patents

Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor

Info

Publication number
AU2003221684A1
AU2003221684A1 AU2003221684A AU2003221684A AU2003221684A1 AU 2003221684 A1 AU2003221684 A1 AU 2003221684A1 AU 2003221684 A AU2003221684 A AU 2003221684A AU 2003221684 A AU2003221684 A AU 2003221684A AU 2003221684 A1 AU2003221684 A1 AU 2003221684A1
Authority
AU
Australia
Prior art keywords
inhibitor
erb
raf
administering
treatment method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003221684A
Other languages
English (en)
Inventor
Neil Lee Spector
Wenle Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2003221684A1 publication Critical patent/AU2003221684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003221684A 2002-04-08 2003-04-08 Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor Abandoned AU2003221684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37080702P 2002-04-08 2002-04-08
US60/370,807 2002-04-08
PCT/US2003/010747 WO2003086467A1 (en) 2002-04-08 2003-04-08 Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor

Publications (1)

Publication Number Publication Date
AU2003221684A1 true AU2003221684A1 (en) 2003-10-27

Family

ID=29250586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003221684A Abandoned AU2003221684A1 (en) 2002-04-08 2003-04-08 Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor

Country Status (5)

Country Link
US (1) US20050176740A1 (enExample)
EP (1) EP1492568A1 (enExample)
JP (1) JP2005534623A (enExample)
AU (1) AU2003221684A1 (enExample)
WO (1) WO2003086467A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011607A2 (en) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
KR101356748B1 (ko) 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
MX2011012199A (es) 2009-05-15 2011-12-08 Novartis Ag Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
AU2010247412A1 (en) 2009-05-15 2011-11-24 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US8709419B2 (en) * 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
WO2012075327A1 (en) 2010-12-02 2012-06-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods for treating a tumor using an antibody that specifically binds grp94
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
US20200237758A1 (en) * 2014-04-04 2020-07-30 Astrazeneca Ab Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
WO2015182625A1 (ja) * 2014-05-26 2015-12-03 国立大学法人京都大学 Ｒａｓ活性阻害薬及びその用途
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
EP3237639A2 (en) 2014-12-23 2017-11-01 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CA3024465A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
US20210363590A1 (en) 2018-05-21 2021-11-25 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AR007855A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
JPH1112279A (ja) * 1997-06-27 1999-01-19 Microbial Chem Res Found Ｒａｓ蛋白の阻害活性を有する新規なアグライアスタチン立体異性体とそれらの製造法
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds

Also Published As

Publication number Publication date
JP2005534623A (ja) 2005-11-17
US20050176740A1 (en) 2005-08-11
WO2003086467A1 (en) 2003-10-23
EP1492568A1 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
AU2003300200A1 (en) Valve treatment catheter and methods
AU2003202196A1 (en) Devices and methods for heart valve treatment
AU2003259925A1 (en) Well treatment apparatus and method
AU2003256253A1 (en) Aerosol for medical treatment and methods
AU2003300783A1 (en) Vascular assist device and methods
AU2003294483A1 (en) Devices and methods for treatment of vascular aneurysms
AU2003282580A1 (en) Contrast therapy system and method
AU2002346379A1 (en) Dilation catheter assembly and related methods
AU2003287274A1 (en) Devices and methods for treating aortic valve stenosis
AU2003232485A1 (en) Neopeptides and methods useful for detection and treatment of cancer
AU2002326600A1 (en) Side-exit catheter and method for its use
AU2003248837A1 (en) Methods and devices for treating aneurysms
AU2003209202A1 (en) Method and device to treat vulnerable plaque
AU2003245712A1 (en) Infusion device and method thereof
AU2002325435A1 (en) Medication and method for treating pathological syndrome
AU2003237407A1 (en) Catheter systems and method for placing bi-ventricular pacing leads
AU2003264053A1 (en) Treatment for acne vulgaris and method of use
AU2003272406A1 (en) Device and method for treating restenosis
AU2003207043A1 (en) Massager and massaging method
GB2390025B (en) Dermatological treatment apparatus and method
AU2003232044A1 (en) Composition and method for dermatological treatment
AU2003217832A1 (en) Catheter for treating vulnerable plaque
AU2002338191A1 (en) Surface treatment system and surface treatment method
AU2003256526A1 (en) Arrangements and methods for treating a subject
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase